Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Barzolvolimab - Celldex Therapeutics Inc

Next Previous
Drug Profile

Barzolvolimab - Celldex Therapeutics Inc

Alternative Names: Anti-KIT monoclonal antibody - Celldex Therapeutics; CDX-0159

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Toronto; Yale University School of Medicine
  • Developer Celldex Therapeutics Inc
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Chronic urticaria
  • Phase II Prurigo nodularis
  • Discontinued Eosinophilic oesophagitis

Most Recent Events

  • 21 Jul 2026 Adverse event, pharmacodynamic and efficacy data from a phase II trial in Prurigo nodularis released by Celldex Therapeutics
  • 21 Jul 2026 Celldex Therapeutics terminates a phase II trial in prurigo nodularis in Canada, Croatia, Germany, Multinational, Poland, Spain, and the USA (NCT06366750)
  • 14 Jun 2026 Updated efficacy data from a phase-II clinical trials in Chronic-urticaria released by Celldex Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top